Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays

Monoclonal antibodies (mAbs) are a leading class of biotherapeutics. In oncology, patients often fail on early lines of biologic therapy to a specific target. Some patients may then enroll in a new clinical trial with a mAb specific for the same target. Therefore, immunoassays designed to quantify t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dengler, Andrew F., Weiss, Rachel, Truong, Tiffany, Irvin, Susan C., Gadhia, Nidhi, Hassanein, Mohamed, Georgaros, Camille, Taylor, Jessica-Ann, Paccaly, Anne, Sumner, Giane, Andisik, Matthew D., Torri, Albert, Partridge, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490245/
https://www.ncbi.nlm.nih.gov/pubmed/34608545
http://dx.doi.org/10.1208/s12248-021-00643-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490245/
https://www.ncbi.nlm.nih.gov/pubmed/34608545
http://dx.doi.org/10.1208/s12248-021-00643-4

Ejemplares similares